logo
  Join        Login             Stock Quote

Perception, Opportunity in Volatility - Research & Analysis on Human Genome Sciences and Merck & Co., Inc.

Tuesday, February 7, 2012 9:00 AM


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=848978&ProfileId=051205&sourceType=1

HONG KONG -- (Marketwire) -- 02/07/12 -- This morning, www.MarketFoundations.com announced new reports highlighting Human Genome Sciences (NASDAQ: HGSI) and Merck & Co., Inc. (NYSE: MRK). Free research downloads are available at www.MarketFoundations.com/index.php?coa=HGSI&cob=MRK.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Market Foundations is releasing new coverage on Human Genome Sciences for its current position within the healthcare industry. Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. GlaxoSmithKline (GSK) is a HGS partner in the co-development and commercialization of BENLYSTA. The full research report on Human Genome Sciences (NASDAQ: HGSI) is available here: www.MarketFoundations.com/index.php?coa=HGSI.

Market Foundations has released research on Merck & Co., Inc. for its changing role within the healthcare industry. Merck & Co., Inc. (Merck) is a global health care company. Merck delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates in four segments: Pharmaceutical, Animal Health, Consumer Care and Alliances. The full research report on Merck & Co., Inc. (NYSE: MRK) is available here: www.MarketFoundations.com/index.php?cob=MRK.

About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.

Contact:

Gemma Cunningham
Email: Email Contact
www.MarketFoundations.com

(Source: Market Wire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.